FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 25, 2026
Nika Pharmaceuticals, Inc. (NIKA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $2,932 in cash and investments and $340,624 in total debt.
Revenue
$0
Net income
$-76,398
+20.2% vs prior year
Operating cash flow (TTM)
$-69,144
-1.5% vs year-ago TTM
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
1.05B
+2.1% vs prior year
Net cash
$-337,692
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NIKA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CO
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1145604
- Former names
- CENTENNIAL GROWTH EQUITIES INC (until Aug 15, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Operating income | -$76,398 | -$95,792 | -$64,833 | -$3.2M | -$14,712 |
| Net income | -$76,398 | -$95,792 | -$64,833 | -$3.2M | -$14,712 |
| Diluted EPS | $0.00 | $0.00 | — | $0.00 | — |
| Operating cash flow | -$79,654 | -$154,932 | -$64,833 | $33,715 | $14,712 |
| Total assets | $20,996 | $17,934 | $19,596 | $864 | $399 |
| Total liabilities | $318,624 | $239,164 | $101,745 | $18,180 | $24,018 |
| Stockholders' equity | -$297,628 | -$221,230 | -$82,149 | -$17,316 | -$23,619 |
| Cash and investments | $1,889 | $2,083 | $19,596 | $864 | $399 |
| Total debt | $318,624 | $239,164 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
All 71 Nika Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.